Expert Interviews

Fixed-dose ibrutinib plus venetoclax produces limited second malignancies among patients with chronic lymphocytic leukemia, says Paolo Ghia, MD, PhD.

Dr. Hutson explains approaches to educating patients on potential side effects of immunotherapy combinations for kidney cancer, empowering them to manage side effects and maintain quality of life while getting clinical benefit from these life-extending therapies.

Kidney cancer, which once had few treatment options, now has multiple oral targeted therapies leading to improved survival; immunotherapy combinations further increased clinical benefit over previous options, providing clinicians several approved regimens from which to choose the optimal therapy for each patient.

An overview of results from the phase III randomized ADAURA Trial.

A review of Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC.

Dr Narjust Florez discusses the hepatoxicity associated with KRAS G12C inhibitors, noting both adagrasib and sotorasib pose liver damage risks, but real-world data suggests adagrasib may have a lower risk; she emphases the importance of considering other causes of hepatoxicity before attributing it solely to these therapies.

Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.

Discussion on the treatment for borderline resectable patients with NSCLC.

CodeBreaK 100 compares the safety and efficacy of pembrolizumab combined with adagrasib or sotorasib in treating KRAS G12C NSCLC, noting sotorasib has a longer presence and familiarity in clinical use.

Adding trastuzumab emtansine to tucatinib appears to significantly improve progression-free survival in patients with metastatic HER2-positive breast cancer, says Sara Hurvitz, MD, FACP.

Luciano Costa, MD, reviews recent data from the PERSEUS trial investigating the combination of daratumumab, bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients.

An overview of bispecific antibodies available for the treatment of patients with relapsed/refractory multiple myeloma.

A panel of multiple myeloma specialists discuss emerging data and ongoing research that are informing treating paradigms for patients with multiple myeloma.

Caitlin Costello, MD, discusses her insights and considerations when choosing the next line of therapy in a patient with relapsed/refractory multiple myeloma.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss highlights of the conference in a game show–style production.

Alykhan Nagji, MD, provides a brief overview of the landscape surrounding the treatment of patients with stage-III resectable NSCLC.

The panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.

Drs Ciombor and Ahn discuss emerging HER2-targeted therapies in colorectal cancer, including antibody-drug conjugates and novel antibodies.

A panel of experts on multiple myeloma reviews GPRC5D-related oral toxicities seen in patients receiving treatment.